In vivo neutralization of duck hepatitis B virus by antibodies specific to the N-terminal portion of pre-S protein
- PMID: 1718087
- DOI: 10.1016/0042-6822(91)90796-e
In vivo neutralization of duck hepatitis B virus by antibodies specific to the N-terminal portion of pre-S protein
Abstract
The neutralization of duck hepatitis B virus (DHBV) infection using antibodies directed against the N-terminal portion of the large surface protein was examined in vitro and in vivo. We demonstrate here that a monoclonal antibody, directed against an epitope mapped between aa 77 and aa 100 on the DHBV pre-S, exerts a similar neutralizing activity (77%) both in vivo and in vitro. Furthermore, we have found that a polyclonal antiserum raised against the bacterially expressed 131 first amino acids of the DHBV pre-S region abolished the infectivity of DHBV in ducklings. Therefore, antibodies against a peptide representing most of the DHBV pre-S region (1-131) or a monoclonal antibody specific to an epitope within this region neutralizes in vivo DHBV infectivity.
Similar articles
-
Virus-neutralizing monoclonal antibody to a conserved epitope on the duck hepatitis B virus pre-S protein.J Virol. 1990 Mar;64(3):1290-7. doi: 10.1128/JVI.64.3.1290-1297.1990. J Virol. 1990. PMID: 1689393 Free PMC article.
-
Identification of major antigenic domains of duck hepatitis B virus pre-S protein by peptide scanning.Virology. 1994 Apr;200(1):72-8. doi: 10.1006/viro.1994.1164. Virology. 1994. PMID: 7510440
-
Fine mapping of neutralization epitopes on duck hepatitis B virus (DHBV) pre-S protein using monoclonal antibodies and overlapping peptides.Virology. 1993 Jan;192(1):217-23. doi: 10.1006/viro.1993.1024. Virology. 1993. PMID: 7685963
-
In vivo selection of duck hepatitis B virus pre-S variants which escape from neutralization.Virology. 1997 Aug 4;234(2):291-9. doi: 10.1006/viro.1997.8665. Virology. 1997. PMID: 9268160
-
Duck hepatitis B virus (DHBV) as a model for understanding hepadnavirus neutralization.Arch Virol Suppl. 1993;8:133-9. doi: 10.1007/978-3-7091-9312-9_14. Arch Virol Suppl. 1993. PMID: 8260858 Review.
Cited by
-
Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.Antimicrob Agents Chemother. 2000 Jan;44(1):111-22. doi: 10.1128/AAC.44.1.111-122.2000. Antimicrob Agents Chemother. 2000. PMID: 10602731 Free PMC article.
-
Identification of antigenic regions of duck hepatitis B virus core protein with antibodies elicited by DNA immunization and chronic infection.J Virol. 2004 Feb;78(4):1945-53. doi: 10.1128/jvi.78.4.1945-1953.2004. J Virol. 2004. PMID: 14747559 Free PMC article.
-
Hepatitis B virus biology.Microbiol Mol Biol Rev. 2000 Mar;64(1):51-68. doi: 10.1128/MMBR.64.1.51-68.2000. Microbiol Mol Biol Rev. 2000. PMID: 10704474 Free PMC article. Review.
-
Residues critical for duck hepatitis B virus neutralization are involved in host cell interaction.J Virol. 1999 Apr;73(4):2569-75. doi: 10.1128/JVI.73.4.2569-2575.1999. J Virol. 1999. PMID: 10074101 Free PMC article.
-
2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo.Antimicrob Agents Chemother. 1996 Feb;40(2):448-53. doi: 10.1128/AAC.40.2.448. Antimicrob Agents Chemother. 1996. PMID: 8834896 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources